Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer

NCT03290937 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Carcinoma
Stage IV Colorectal Cancer AJCC v8
Stage IVA Colorectal Cancer AJCC v8
Stage IVB Colorectal Cancer AJCC v8
Stage IVC Colorectal Cancer AJCC v8

Interventions

BIOLOGICAL: Cetuximab
DRUG: Irinotecan Hydrochloride
OTHER: Pharmacodynamic Study
BIOLOGICAL: Utomilumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]